Cethromycin versus clarithromycin for community-acquired pneumonia: Comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2037-2047

  English, Marci L ^a   Fredericks, Christine E ^a   Milanesio, Nancy A ^a   Rohowsky, Nestor ^a   Xu, Ze Qi ^a   Jenta, Tuah R J ^a   Flavin, Michael T ^a   Eiznhamer, David A ^a  

^a Advanced Life Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETHROMYCIN; CLARITHROMYCIN; PLACEBO;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT CARE; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; ETHNIC GROUPS; FEMALE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; PNEUMONIA; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863373784     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05596-11     Document Type: Article

References (38)

1. Advanced Life Sciences, Inc. 2009. FDA Anti-Infective Drugs Advisory Committee held on June 2, 2009 to discuss NDA 22-398 for cethromy- cin oral tablets. http://www.fda.gov/downloads/AdvisoryCommittees / CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee /UCM166989.pdf. Accessed 14 December 2010.
2. Bertrand D, Bertrand S, Neveu E, Fernandes P. 2010. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54: 5399-5402.
3. Brueggemann AB, et al. 2000. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 44: 447-449. (Pubitemid 30060751)
4. Capobianco JO, et al. 2000. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:1562-1567. (Pubitemid 30340795)
5. Douthwaite S, Champney WS. 2001. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J. Antimicrob. Chemother. 48(Suppl 2):1-8.
6. Drake C, Barenfanger J, Lawhorn J, Verhulst S. 2005. Comparison of Easy-Flow Copan Liquid Stuart's and Starplex Swab transport systems for recovery of fastidious aerobic bacteria. J. Clin. Microbiol. 43:1301-1303. (Pubitemid 40364954)
7. Eiznhamer DA, et al. 2007. In vitro activity of cethromycin, a novel antibiotic under clinical development, against S. pneumoniae not susceptible to telithromycin. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1633.
8. Endeman H, et al. 2008. Clinical features predicting failure of pathogen identification in patients with community acquired pneumonia. Scand. J. Infect. Dis. 40:715-720.
9. File TM, Jr. 2004. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am. J. Med. 117(Suppl 3A):39S-50S.
10. File TM, Jr, et al. 2004. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125:1888-1901.
11. File TM. 2009. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J. Manag. Care Pharm. 15(Suppl):S5-S11.
12. Fleming TR, Powers JH. 2008. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl 3):S108-S120.
13. Franceschi F, Kanyo Z, Sherer EC, Sutcliffe J. 2004. Macrolide resistance from the ribosome perspective. Curr. Drug Targets Infect. Disord. 4:177-191. (Pubitemid 39236729)
14. Goldstein EJ, et al. 2001. In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 45:2363-2367. (Pubitemid 32666201)
15. Goossens H, et al. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-987.
16. Higgins K, et al. 2008. Overview of recent studies of community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl 3): S150-S156.
17. Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. 2004. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607. (Pubitemid 38141723)
18. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: cause, challenge and responses. Nat. Med. 10(Suppl 12):S122-S129. (Pubitemid 40018235)
19. Lode H. 2010. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am. J. Med. 123(Suppl 4):S26-S38.
20. Mandell LA, et al. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl 2):S27-S72. (Pubitemid 46290553)
21. Mason CK, et al. 2010. Optimisation of storage conditions for maintaining culturability of penicillin-susceptible and penicillin-resistant isolates of Streptococcus pneumoniae in transport medium. Br. J. Biomed. Sci. 67:1-4.
22. Mason EO, Jr, et al. 2003. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides. Antimicrob. Agents Chemother. 47:166-169.
23. Mathers Dunbar L, Hassman J, Tellier G. 2004. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin. Ther. 26: 48-62. (Pubitemid 38241522)
24. Metlay JP. 2004. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect. Dis. Clin. North Am. 18:777-790. (Pubitemid 39536008)
25. Murphy TF. 2008. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. Clin. Infect. Dis. 47(Suppl 3):S145-S149.
26. Muto CA, et al. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26:273-280. (Pubitemid 40445086)
27. Niederman MS. 2004. Review of treatment guidelines for community-acquired pneumonia. Am. J. Med. 117(Suppl 3A):51S-57S.
28. Nilius AM, et al. 2001. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob. Agents Chemother. 45:2163-2168. (Pubitemid 32591721)
29. Nugent R, Back E, Beith A. 2010. The race against drug resistance. Center for Global Development's Drug Resistance Working Group, Washington, DC.
30. Pépin J, et al. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260. (Pubitemid 41532667)
31. Shortridge VD, et al. 2002. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob. Agents Chemother. 46:783-786. (Pubitemid 34157664)
32. Spellberg B, Fleming TR, Gilbert DN. 2008. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl 3): S105-S107.
33. Tellier G, et al. 2004. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 54:515-523. (Pubitemid 39177479)
34. U. S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). 2009. Guidance for industry. Patient reported outcome measures: use in medical product development to support labeling claims.
35. U. S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2010. Guidance for industry. Qualification process for drug development tools (draft).
36. von Eiff C, Peters G. 2002. Comparative in vitro activity of ABT-773 and two macrolides against staphylococci. J. Antimicrob. Chemother. 49:189-192. (Pubitemid 34100666)
37. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. 2010. Deaths: final data for 2007. Natl. Vital Stat. Rep. 58:1-136.
38. Zhanel GG, et al. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62:13-59. (Pubitemid 34169425)